

INTERNATIONAL CONGRESS

MULTIPLE MYELOMA *and related malignancies*



Picture by Dr. Gaetano Scanni

5th Edition 2020

Webinar

Presidents

Prof. Angelo Vacca
Prof. Pellegrino Musto
Prof. Roberto Ria

November 5-7, 2020

Under the auspices of:



UNIVERSITÀ
DEGLI STUDI DI BARI
ALDO MORO

SIE

Società Italiana di Ematologia



Società Italiana di Ematologia Sperimentale

SIMI
SOCIETÀ ITALIANA
DI MEDICINA INTERNA
Patrocinio

In the last 10 years significant advancements in the understanding of the pathophysiology of multiple myeloma and related malignancies have led to the adoption of new effective and safe therapies. Thus, the time has come for a thorough biological and clinical update.

In planning this international meeting, we have indeed kept in mind this aim which will hopefully provide specialists in Hematology, Oncology, Immunology, Internal Medicine, Infectious diseases, Orthopedy, Radiology and Radiotherapy, as well as Biologists and Biotechnologists, and young researchers, residents, doctoral and undergraduate students with a great opportunity to deepen and update their knowledge on the available and emerging developments in the biology and management of multiple myeloma and related malignancies.

A number of internationally recognized speakers, are expected to deliver state-of-the-art lectures on cutting edge topics. These will include genetic and epigenetic features of myeloma biology, molecular and biological mechanisms of disease progression, new prognostic factors and novel approaches for evaluate the response to therapy, new therapeutic molecules and combinations thereof specifically targeting tumor cells and/or their microenvironment. Autologous and allogeneic stem cell transplantation will also be the object of intensive scrutiny. Based on these premises, we are confident that at the end of the meeting all of us will be enriched with fresh stimuli and renewed enthusiasm, with the deep awareness that the enduring challenges posed by multiple myeloma and cognate tumors may now be faced with more rational and more effective achievements.

Angelo Vacca, Pellegrino Musto, Roberto Ria

- 09.20-09.30 Welcome speech and orientation
Angelo Vacca, Pellegrino Musto, Roberto Ria
- 09.30-12.40 **Workshop I**
Biology, Bone Disease and Immunodeficiency of Myeloma
Coordinator: **Angelo Vacca (Bari, IT)**
- 09.30-09.50 **Kim De Veirman (Brussels, BE)**
Bone marrow microenvironment and MGUS progression
- 09.50-10.10 **Niccolò Bolli (Milan, IT)**
Genomic profiling of monoclonal gammopathies: MGUS/SM and overt MM
- 10.10-10.30 **Cirino Botta (Cosenza, IT)**
Single cell characterization of MM immune microenvironment
- 10.30-10.50 **Nicola Giuliani (Parma, IT)**
Bone destruction in MM: can biology help the clinician?
- 10.50-11.10 **G. David Roodman (Indianapolis, USA)**
Myeloma bone disease: Pathogenesis and Treatment
- 11.10-11.20 *Pause*
- 11.20-11.40 **Ivan Borrello (Baltimore, USA)**
Marrow Infiltrating Lymphocytes: Insights into their biology and clinical use
- 11.40-12.00 **Angelo Vacca (Bari, IT)**
Endothelial cells and fibroblasts as immunosuppressive agents in MM
- 12.00-12.20 **Massimo Massaia (Cuneo, IT)**
Decoding the immune suppressive network with V γ 9V δ 2 T cells
- 12.20-12.40 **Roberto Ria (Bari, IT)**
Prophylaxis of infections in patients with multiple myeloma in the era of the newest drugs

- 15.30-18.40 **Workshop 2**
Diagnosis, Prognosis and Clinical Features
Coordinator: **Gianpietro Semenzato (Padua, IT)**
- 15.30-15.50 **Elena Zamagni (Bologna, IT)**
Imaging techniques and applications in MM
- 15.50-16.10 **Andrew Spencer (Melbourne, AU)**
DNA repair gene mutations in multiple myeloma
- 16.10-16.30 **Aldo M. Roccaro (Brescia, IT)**
Transcriptome of malignant plasma cells
- 16.30-16.50 **Bruno Paiva (Pamplona, ES)**
Circulating tumor cells for non-invasive genetic characterization of MM
- 16.50-17.10 **Hervé Avet-Loiseau (Toulouse, FR)**
How to define high-risk myeloma
- 17.10-17.20 *Pause*
- 17.20-17.40 **Roger G. Owen (Leeds, UK)**
Evaluation of MRD in MM
- 17.40-18.00 **Maria Victoria Mateos (Salamanca, ES)**
Smoldering myeloma: new concepts in preventing progression
- 18.00-18.20 **Roman Hájek (Ostrava, CZ)**
An importance of real word evidence in multiple myeloma
- 18.20-18.40 **Francesco Di Raimondo (Catania, IT)**
Diagnostic criteria, response assessment, and workup at the end of 2020

- 09.30-12.40 **Workshop 3**
First Line Therapy
Coordinator: **Alessandro Corso (Legnano, IT)**
- 09.30-10.00 **Lecture**
Faith E. Davies (New York - USA)
Is precision medicine a feasible approach to multiple myeloma?
- 10.00-10.20 **Maria Teresa Petrucci (Rome, IT)**
Upfront treatment in young patients: toward new induction regimens
- 10.20-10.40 **Mohamad Mohty (Paris, FR)**
Auto-SCT vs novel agents
- 10.40-11.00 **Alessandro Corso (Legnano, IT)**
Upfront treatment in young patients: what maintenance therapy and how long
- 11.00-11.10 *Pause*
- 11.10-11.30 **Francesca Gay (Turin, IT)**
Treatment of newly diagnosed myeloma in elderly patients
- 11.30-11.50 **Alessandra Larocca (Turin, IT)**
Multiple myeloma and aging
- 11.50-12.10 **Francesca Patriarca (Udine, IT)**
What are the approaches to achieve the best possible outcomes in myeloma?
- 12.10-12.40 **Concluding lecture**
Morie Gertz (Rochester, USA)
Continuous treatment: pro and contras

- 15.30-18.30 **Workshop 4**
Relapsed/Refractory Myeloma and the Newest Drugs
Coordinator: **Roberto Ria (Bari, IT)**
- 15.30-15.50 **Anders Waage (Trondheim, NO)**
Treatment options at first relapse
- 15.50-16.10 **Inger S. Nijhof (Amsterdam, NL)**
Refractory disease
- 16.10-16.30 **Gordon Cook (Leeds, UK)**
New therapeutic approaches for relapsed/refractory patients
- 16.30-16.50 **Paola Neri (Calgary, CA)**
Immunome single cell profiling to identify mechanisms of tumoral escape in Daratumumab-treated Myeloma patients
- 16.50-17.00 *Pause*
- 17.00-17.20 **Paolo Corradini (Milan, IT)**
Car T cells: a new hope?
- 17.20-17.40 **Annie Reale (Melbourne, AU)**
New targets and new approaches: latest advances in extracellular vesicles
- 17.40-18.00 **Niels Van de Donk (Amsterdam, NL)**
The evolving role of immunotherapy in MM patients
- 18.00-18.30 **Concluding lecture**
Herman Einsele (Würzburg, DE)
Bispecific antibodies and novel cellular therapies

- 09.30-12.20 **Workshop 5**
Plasma Cell Dyscrasias, Progression, and Management
Coordinator: **Pellegrino Musto (Bari, IT)**
- 09.30-09.50 **Carolina Terragna (Bologna, IT)**
Role of clonal evolution in MM progression and refractoriness
- 09.50-10.10 **Pellegrino Musto (Bari, IT)**
Management of primary plasma cell leukemia
- 10.10-10.30 **Franco Dammacco (Bari, IT)**
What is new in the diagnosis and treatment of Waldenström's macroglobulinemia
- 10.30-10.50 **Stefan Schönland (Heidelberg, DE)**
New strategies for the treatment of AL amyloidosis
- 10.50-11.00 *Pause*
- 11.00-11.20 **Laura Rosiñol (Barcelona, ES)**
Management of renal impairment in MM
- 11.20-11.40 **Daniele Derudas (Cagliari, IT)**
Monoclonal gammopathies of renal significance
- 11.40-12.00 **Meral Beksac (Ankara, TR)**
Extramedullary myeloma: an unmet need
- 12.00-12.20 Summing-up and Closing
Angelo Vacca, Roberto Ria, Pellegrino Musto

REGISTRATION FEE

The registration fee is 100,00 EUR (+ VAT 22%)

PAYMENT

Payment of registration fee can be made through the website www.meeting-planner.it (select the congress in the section "Calendario eventi" - FAD).

Payments can be made by credit card or by bank transfer (all transaction fees should be paid by the participant).

An invoice will be sent as confirmation of the registration.

CANCELLATION POLICY

Cancellations must be notified in writing to the Conference Secretariat (stella@meeting-planner.it).

For cancellations received by October 15,2020: 100% refund (less a EUR 20,00 of administrative charge).

No refund will be made for cancellations received after that date or for no-shows.

Please note that refunds will only be processed by bank transfer after the Conference dates.

CONTINUING MEDICAL EDUCATION (CME) - event n. 303981

This Congress has been assigned n. 21 credits.

This training event is for 200 attendees. Medical specialists in the following areas: Internal Medicine, Allergology and Clinical Immunology, Hematology, Oncology, Infectious diseases, Radiology, Radiotherapy, Orthopedics and traumatology and Clinical Biochemistry.

Other healthcare professionals: Biologists and Nurses.

CME credits can be claimed and your CME certificate issued only if you:

- have attended the entire training event
- have passed the CME assessment survey (a score of 75% or higher must be attained)

There can be no exceptions to these mandatory steps.

Attendants are also required not to exceed acquiring over 1/3 of their credits for the three-year period (2020-2022) by recruitment invitation.

AIMS OF THE TRAINING PROCESS:

Guidelines, Protocols, Procedures (2)

LANGUAGE

The official language is English.

Recommended devices: PC/LAPTOP/MAC

Browser: GOOGLE CHROME

PROVIDER AND ORGANIZING SECRETARIAT



MEETING PLANNER

Via Divisione Paracadutisti Folgore, 5 - 70125 BARI (Italy)
TEL. +39 080.9905360 • FAX +39 080.9905359 • +39 080.2140203
E-mail: info@meeting-planner.it - www.meeting-planner.it

UNE EN ISO 9001:2015



SEZIONE DI GESTIONE QUALITÀ CERTIFICATA
CERTIFICAZIONE N. 10711

With the unconditional sponsorship of:

